Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Disease × daratumumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 14 Smoldering Multiple Myeloma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmablastic Lymphoma 1 Disease 1

Interventions

Cyclophosphamide 2 deltacortene 1 daratumumab 1 carfilzomib 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Dexamethasone 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡